William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.
Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, the “financial toxicities” of high drug prices, and what could and should be done about it.
Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.
